Sait YEŞİLLİK
(Türkiye Sağlık Bilimleri Üniversitesi, Gülhane Eğitim ve Araştırma Hastanesi, İmmünoloji ve Alerjik Hastalıklar Anabilim Dalı, Ankara, Türkiye)
Fevzi DEMIREL
(Türkiye Sağlık Bilimleri Üniversitesi, Gülhane Eğitim ve Araştırma Hastanesi, İmmünoloji ve Alerjik Hastalıklar Anabilim Dalı, Ankara, Türkiye)
Yıl: 2021Cilt: 19Sayı: 2ISSN: 1308-9234Sayfa Aralığı: 64 - 70İngilizce

42 0
Anxiety and Depression Among Patients with Predominantly Antibody Deficiencies and the Importance of Early Diagnosis
Objective: Diagnostic delay is one of the major problems for patients with predominantly antibody deficiencies (PAD) that can lead to anxiety and depression disorders, like in other chronic diseases. We aimed to detect the frequencies of anxiety and depression in PAD patients. The second aim was to determine the influence of diagnosis delay on the patients’ anxiety and depression. Materials and Methods: In this prospective study, 40 patients and 50 healthy controls answered the Hospital Anxiety and Depression Scale (HADS). We compared the anxiety, depression, and the total scores of the patients and the healthy controls. We divided the patients into two groups as delayed and early diagnosed patients according to median diagnostic delay year and compared the HADS scores of the two groups. Results: The anxiety, depression and the total scores of PAD patients were significantly higher compared to the healthy controls; (p=0.001, p=0.001, p=0.001), respectively. The HADS scores were significantly higher in the delayed diagnosis patient group than the early diagnosed patient group (p=0.001, p=0.003, p=0.001), respectively. We also confirmed this positive relationship between delayed diagnosis and the HADS scores with Spearman’s correlation analysis. Conclusion: We demonstrated that psychiatric disorders such as anxiety and depression are common in PAD patients, and delayed diagnosis strongly affects their anxiety and depression. Collaboration with psychologists and psychiatrists during the management of these patients may improve the quality of their life.
DergiAraştırma MakalesiErişime Açık
  • 1. Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, et al. Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2020;40:24-65.
  • 2. Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005;94:1186-205.
  • 3. Rider NL, Kutac C, Hajjar J, Scalchunes C, Seeborg FO, Boyle M, et al. Health-related quality of life in adult patients with common variable immunodeficiency disorders and impact of treatment. J Clin Immunol 2017;37:461-75.
  • 4. Aghamohammadi A, Moin M, Farhoudi A, Rezaei N, Pourpak Z, Mahalhedi M, et al. Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia. FEMS Immunol Med Microbiol 2004;40:113-8.
  • 5. de Gracia J, Vendrell M, Alvarez A, Pallisa E, Rodrigo MJ, de la Rosa D, et al. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol 2004;4:745-53.
  • 6. Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 2002;109:1001-4.
  • 7. Cadman D, Boyle M, Szatmari P, Offord DR. Chronic illness, disability, and mental and social well being: Findings of the Ontario Child Health Study. Pediatrics 1987;79:805-13.
  • 8. Gathmann B, Mahlaoui N, CEREDIH; Gérard L, Oksenhendler E, Warnatz K, Schulze I, et al. European Society for Immunodeficiencies Registry Working Party. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol 2014;134:116-26.
  • 9. Sidwell RU, Ibrahim MA, Bunker CB. A case of common variable immunodeficiency presenting with furunculosis. Br J Dermatol 2002;147: 364-7.
  • 10. Cunningham-Rundles C. Common variable immune deficiency: Case studies. Blood 2019;134:1787-95.
  • 11. Heath J, Lehman E, Saunders EF, Craig T. Anxiety and depression in adults with primary immunodeficiency: How much do these patients experience and how much do they attribute to their primary immunodeficiency? Allergy Asthma Proc 2016;37: 409-15.
  • 12. Kuburovic NB, Pasic S, Susic G, Stevanovic D, Kuburovic V, Zdravkovic S, et al. Health-related quality of life, anxiety, and depressive symptoms in children with primary immunodeficiencies. Patient Prefer Adherence 2014;8:323-30.
  • 13. Tabolli S, Giannantoni P, Pulvirenti F, La Marra F, Granata G, Milito C, et al. Longitudinal study on health-related quality of life in a cohort of 96 patients with common variable immune deficiencies. Front Immunol 2014;5:605.
  • 14. Quinti I, Di Pietro C, Martini H, Pesce AM, Lombardi F, Baumghartner M, et al. Health related quality of life in common variable immunodeficiency. Yonsei Med J 2012;53:603-10.
  • 15. Aghamohammadi A, Montazeri A, Abolhassani H, Saroukhani S, Pourjabbar S, Tavassoli M, et al. Health-related quality of life in primary antibody deficiency. Iran J Allergy Asthma Immunol 2011;10:47-51.
  • 16. Soresina A, Nacinovich R, Bomba M, Cassani M, Molinaro A, Sciotto A, et al. Italian network for primary immunodeficiencies. The quality of life of children and adolescents with X-linked agammaglobulinemia. J Clin Immunol 2009;29:501-7.
  • 17. Zebracki K, Palermo TM, Hostoffer R, Duff K, Drotar D. Health-related quality of life of children with primary immunodeficiency disease: A comparison study. Ann Allergy Asthma Immunol 2004;93:557-61.
  • 18. Zigmond AS, Snaith PR. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70.
  • 19. Aydemir Ö, Güvenir T, Küey L, Kültür S. Validity and reliability of the Turkish version of Hospital anxiety and depression scale. Türk Psikiyatri Dergisi 1997;8: 280-7.
  • 20. Buin E, Pavin EJ, Silveira MSVM. High anxiety and depressive symptoms in partners of type 1 diabetes persons in a sample of the Brazilian population. Diabetol Metab Syndr 2020;12:23.
  • 21. Tat TS. Higher levels of depression and anxiety in patients with chronic urticaria. Med Sci Monit 2019;25:115-20.
  • 22. Camara A, Sow MS, Touré A, Sako FB, Camara I, Soumaoro K, et al. Anxiety and depression among HIV patients of the infectious disease department of Conakry University Hospital in 2018. Epidemiol Infect 2020;148: e8.
  • 23. Agus DF, Effendy E, Camellia V. Screening of anxiety and depression related CD4 count of people living with HIV/AIDS with anti-retroviral in Medan, Indonesia. J Med Sci 2019;7:2590-94.
  • 24. Delamater AM, Guzman A, Aparicio K. Mental health issues in children and adolescents with chronic illness. Int J Hum Rights Healthc 2017;10:163-73.
  • 25. Howard V, Greene JM, Pahwa S, Winkelstein JA, Boyle JM, Kocak M, et al. The health status and quality of life of adults with X-linked agammaglobulinemia. Clin Immunol 2006;118:201-8
  • 26. Slade CA, Bosco JJ, Giang TB, Kruse E, Stirling RG, Cameron PU, et al. Delayed diagnosis and complications of predominantly antibody deficiencies in a cohort of Australian Adults. Front Immunol 2018;9:694.
  • 27. Campbell M, Clarke A, Symes A Workman S, Stauss H, Webster AD. Investigating the effectiveness, acceptability and impact on healthcare usage of providing a cognitive-behavioural based psychological therapy service for patients with primary antibody deficiency. J Clin Immunol 2018;38:214-20.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.